New hope for liver cancer patients when immunotherapy stops working

NCT ID NCT07495579

Not yet recruiting Disease control Sponsor: Asan Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests two oral drugs, lenvatinib and regorafenib, in 146 adults with advanced liver cancer that cannot be surgically removed and has worsened after initial immunotherapy. The study has two parts: one for patients with better liver function and one for those with reduced liver function. Researchers will measure how long the drugs can control cancer growth and monitor side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenvatinib or regorafenib
What this could lead to: If successful, this could provide a new treatment option for people with advanced liver cancer whose first immunotherapy-based treatment stopped working.
What could go wrong: This is a phase 2 trial, so it is still early. The drugs may not work as hoped, and side effects like fatigue, high blood pressure, or liver problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Asan Medical Center

Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.